93 results about "Cell bank" patented technology

The application discloses a low-orbit satellite congestion control method based on an artificial immune algorithm, which comprises the following steps: a satellite node periodically monitors the occupancy rate of an output queue in each direction, when congestion is detected, the satellite generates a congestion warning packet as an antigen and sends it to a directly adjacent node; the adjacent node receiving the congestion warning packet finds a matching item of an affected destination node in a historical memory cell library through the similarity between the current scene and the historical record, as the routing strategy of the destination node; when no match is found, the optimal bypass strategy is determined based on the direction of the congestion link and the position information of the satellite; the satellite comprehensively evaluates the generated control strategy within a time window; when the affinity continues to fail to reach a threshold, the satellite continuously monitors the queue occupancy rate change trend, and when it is found that a continuous multiple periods show an upward trend, the shunt proportion is increased; the application improves the response speed of the congestion control, network performance and service quality.

The invention relates to the technical field of medical information systems, in particular to a blood smear abnormal cell intelligent recognition system and method based on deep learning. The multi-stage convolutional neural network module is in data connection with the image acquisition module, and the abnormal cell bank module is in data connection with the multi-stage convolutional neural network module; the knowledge graph module is in data connection with the abnormal cell bank module, and the blood index calculation module is in data connection with the multistage convolutional neural network module and the abnormal cell bank module and is used for calculating various blood indexes; generating a graphical display result of the blood indexes; the result output module is in data connection with the knowledge graph module and the blood index calculation module; according to the blood disease diagnosis method and system, the whole process from image acquisition to diagnosis report generation can be automatically completed, detailed analysis results and diagnosis suggestions can be provided for doctors, and the efficiency and accuracy of blood disease diagnosis are greatly improved.

Battery arrays are provided for traction battery packs. An exemplary battery array may include a thermal barrier and venting system for mitigating cell-to-cell and / or cell bank-to-cell bank thermal propagation. The battery thermal barrier and venting system may further include one or more vent passageways for establishing dedicated venting paths for expelling gases and other effluents from the battery array during battery thermal events.

The invention discloses a construction method of a somatic cell bank, which belongs to the technical field of somatic cell banks, and comprises the following steps: collection and identification of cell strains, culture and passage of the cell strains, cryopreservation and preservation of the cell strains, cell quality control and detection, updating and recovery of the cell bank, and safety management of the cell bank. The construction efficiency of the cell bank is improved by optimizing the steps of cell culture, passage, cryopreservation and the like, the stability and the activity of cells in the long-term storage process are ensured by adopting an advanced freezing technology and a preservation system, a perfect cell bank information management system is established, detailed information of each cell strain is recorded and managed, and the cell bank management efficiency is improved. The traceability reliability of the cells is ensured, a cell bank safety management system is established, and a plurality of measures are adopted to protect cell resources in the cell bank from being lost and damaged.

A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.

In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof to provide immune compatible, allogeneic cell therapies. In the various aspects and embodiments, the cell populations and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the populations by gene editing, and methods for cell therapy involving cells or tissues derived from the cell populations (including but not limited to hematopoietic stem cells, or "HSCs", progenitors, or progenies thereof).

The present invention relates to a method of establishing a prediction regarding the development of a type of solid cancer in an individual, comprising: (i) collecting a biological sample that includes lymphocytes of said individual, (ii) sequencing, using NGS techniques, the mRNA associated with the V(D)J regions of the TCRs of the lymphocytes collected in the previous step, (iii) removing from the TOR repertoire obtained in the previous step the TOR sequences that are specific to other diseases than said solid cancer, (iv) using artificial intelligence algorithms to compute a predictive score for the probability that said TOR repertoire is specific for said type of cancer and (v) based on said predictive score determining the probability of said individual of developing said type of solid cancer.

Circuit design techniques can use a trained predictor to predict key dynamic current metrics (such as peak current, peak time, pulse width and total charge) for a gate in a circuit library, where the predictor has been trained over different combinations of different input transition slews and different output fanout models. A dynamic current model solver can be used for a gate in the cell library to derive waveforms (of current versus time) for the different combinations, and a predictor, such as a neural network, can be trained with the outputs from the solver for the different combinations. The trained predictor can be used in a runtime simulation to solve for the dynamic current demand model of the various gates in a circuit design (such as all of the gates in an integrated circuit).

This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.

1. Name of the Design Product: Intelligent Environment Detector (OSD-IWIFI). 2. Use of the Design Product: This design is used for environmental monitoring in cell banks, cryogenic automated storage equipment, liquid nitrogen tanks, ultra-low temperature refrigerators, refrigerators, transfer tanks, thawing instruments, cold storage, etc. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective View 1.

This vector set is induced into host cells, and cells for producing heteromultimeric proteins are selected from the host cells into which has the vector set is introduced. vector set is a set of a first expression vector and a second expression vector, wherein an expression cassette of at least one subunit X which is a part of a subunit constituting a heteromultimeric protein is contained in both the first expression vector and the second expression vector and from among the subunits constituting the heteromultimeric protein, an expression cassette of the remaining subunit Y excluding the subunit X is contained for each type in one among the first expression vector and the second expression vector.

Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of:(1) providing Rag 1 and / or Rag 2 gene knockout human pluripotent stem cells bearing genes encoding a T cell receptor specific for a desired antigen, and(2) inducing T cells from the pluripotent stem cells of step (1). Further provided are a cell-based immunotherapy method that uses the T cells for the cell-based immunotherapy and an iPS cell bank for the cell-based immunotherapy.

The present invention discloses an in-vitro culture, induction, activation and cryopreservation method and cell bank establishment for immune cells. The method includes the follows: using a dedicated amplification medium of immune cells to perform first-stage amplification culture on mononuclear cells to obtain preliminarily amplified immune cells; using a dedicated induction medium of immune cells to perform second-stage induction and amplification culture on the preliminarily amplified immune cells to obtain induced immune cells; using a dedicated activation medium of immune cells to perform third-stage activation and amplification culture on the induced immune cells to obtain a large number of immune cells with activation functions; using a dedicated cryopreserving fluid of immune cells to cryopreserve the immune cells to obtain cryopreserved immune cells; and performing preservation according to ABO / RH typing and HLA typing; and establishing an information file of immune cells for retrieval to construct an immune cell bank.

The invention discloses a line establishment method and a culture system of bovine trophoblast stem cells. The stem cell line is obtained by separation and induction from bovine blastocyst. The embryonic stem cell line has stability. The method can be applied to various life science and medical fields such as bovine animal breeding and breeding, gene editing models, animal cloned donor cells, medical musculoskeletal injury experiments, drug development carriers, vaccine production cell banks, embryo quality analysis and the like, and can be applied to large-scale production and application.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

A method is derived for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.

To provide compositions for determining the efficacy and potency of a vaccine preparation.SOLUTION: Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots, these cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are counted, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of molecular biology, and particularly relates to a nucleic acid sequence combination for mycoplasma detection, a kit and a use method of the kit. The detection kit comprises a PCR (Polymerase Chain Reaction) specific primer probe, a buffer solution, Taq enzyme and an internal quality control (IC), wherein the primer probe comprises forward and reverse amplification primers aiming at mycoplasma and an internal standard and a detection probe; the sequences of the primers are shown as SEQ ID NO.1-SEQ ID NO.7 respectively. The kit disclosed by the invention can be used for detecting mycoplasmas and accurately identifying whether various biological samples such as cell banks, production raw materials, virus seeds, cell cultures and the like are polluted by the mycoplasmas, and has high sensitivity, specificity and detection accuracy. Meanwhile, by adding internal quality control (IC), whether the to-be-detected sample inhibits the amplification reaction or not can be judged, and a false negative result is prevented from being generated.

The present invention relates to a method for mass-producing, with high-purity and high-efficiency, extracellular vesicles by using a novel cell bank construction strategy, and extracellular vesicles produced therefrom. According to one embodiment of the present invention, extracellular vesicles can be mass-produced with high purity and high efficiency while the characteristics of genetically modified or unmodified cells are stably maintained through the construction of a novel cell bank, and the produced extracellular vesicles can be effectively used as a pharmaceutical composition for preventing or treating diseases and a functional cosmetic composition.

This application discloses a muscle stem cell resuscitation and protection washing solution, a quality assessment kit, and a method of use, belonging to the field of cell biology technology. In this application, vitamin E succinate and mannan peptide are used as core antioxidant components, synergistically combined with Gynostemma pentaphyllum polysaccharide, Portulaca oleracea polysaccharide, trehalose, L-proline, and magnesium sulfate heptahydrate to construct a four-in-one resuscitation and protection washing solution that provides isotonic buffering, extracellular protection, intracellular protein stabilization, antioxidant effects, and mitochondrial stabilization. This increases the survival rate of muscle stem cells after resuscitation to over 93%. The kit integrates a multi-dimensional detection system for cell resuscitation and protection washing solution, cell viability, proliferation rate, Pax7 / MyoD double-positive stemness assessment, and cryopreservation damage, achieving closed-loop management of the entire process of muscle stem cell resuscitation, protection, and quality assessment. The double-positive rate of stemness markers reaches over 90%, providing reliable quality assurance for cell bank management and clinical applications.

The present disclosure relates to a method for producing mesenchymal stem cells for therapeutic applications. The method comprises culturing of MSCs to obtain heterogeneous population. This heterogeneous population of MSCs were subjected to droplet encapsulation media to obtain a population of microfluidic droplets preferably comprising a single MSC; providing the population of microfluidic droplets to a microfluidics device; and identifying and selecting a homogeneous population of MSCs having medium size in the range of 15 to 30 μm showing high expression of cell surface markers (CD73, CD90) and increased expression of genes, such as COL12 A1; IGFBP5; THBS2; GREM1 and CDH2 genes. The MSCs having medium size are further cryopreserved to obtain a cell bank of MSCs with better stability and therapeutic potential in treating diseases like auto immune diseases.

The invention discloses a stem cell culture generation identification method based on an epigenetics clock. Belongs to the field of biotechnology and molecular biology, and designs a specific multiple PCR primer pool and establishes a high-precision generation prediction model by screening eight CpG sites highly related to stem cell replicative senescence. The method comprises the following steps: firstly, carrying out hydrosulfite conversion on sample DNA (Deoxyribonucleic Acid), carrying out targeted amplification by adopting a primer group with an optimized ratio, calculating a methylation level through high-throughput sequencing, and substituting into a formula to output a result. The model has small mean absolute error and is significantly related to aging function indexes. Compared with traditional chip detection, the cost is reduced, the detection period is shortened, and the method is suitable for release inspection of stem cell treatment products, anti-aging drug screening and cell bank quality management.

The invention relates to a qualification method to qualify a batch of undifferentiated adult stem cells having the potential of differentiating along the hepatic lineage as pharmaceutically active, wherein pharmaceutically active indicates that the batch is actually capable of producing sufficiently differentiated and / or functional and / or viable hepatocyte-like cells, so that the undifferentiated adult stem cells in said batch or the extracellular vesicles (EVs) derived therefrom are suitable for use in the therapeutic treatment of a subject suffering from a health condition or disease or are suitable to establish a Master Cell Bank from which sufficiently differentiated and / or functional and / or viable hepatocyte-like cells may subsequently be produced.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

The present invention discloses a method for screening, activating, amplifying and cryopreserving mesenchymal stem cells in vitro and establishing a cell bank of mesenchymal stem cells. The method includes the following steps: using a dedicated primary screening medium of mesenchymal stem cells for first-stage screening culture to obtain purified mesenchymal stem cells; using a dedicated activation and amplification medium of mesenchymal stem cells to perform second-stage activation and large-scale amplification culture on the purified mesenchymal stem cells to obtain a large number of mesenchymal stem cells with activation functions; using a dedicated cryopreserving fluid of mesenchymal stem cells to cryopreserve the stem cells and performing preservation according to ABO / RH typing and HLA typing; and establishing an information file for retrieval to construct a mesenchymal stem cell bank.

The invention provides a method for constructing a hepatic progenitor cell-like cell bank, including successively performing following processes to human primary hepatocyte cultures from different donor sources: transformation-culture, cryopreservation treatment, proliferation-culture, a first subculture treatment, virus infection, a second subculture treatment, continuous selection-culture and continuous subculture. In the method for constructing a heterogenous immortal hepatic progenitor cell-like cell bank of the present invention, the human primary hepatocyte culture of each of the donor sources is transformation-cultured before the proliferation-culture, which is beneficial in endowing the human primary hepatocyte cultures with good proliferation performance. Once combined with subsequent controlling of culture parameter, the immortal hepatic progenitor cell-like cell lines obtained from different donor sources may have good in vitro proliferation ability. The invention also provides an application of the hepatic progenitor cell-like cell bank and cell lines obtained by the construction method.

The invention relates to a qualification method to qualify a batch of undifferentiated adult stem cells having the potential of differentiating along the hepatic lineage as pharmaceutically active, wherein pharmaceutically active indicates that the batch is actually capable of producing sufficiently differentiated and / or functional and / or viable hepatocyte-like cells, so that the undifferentiated adult stem cells in said batch or the extracellular vesicles (EVs) derived therefrom are suitable for use in the therapeutic treatment of a subject suffering from a health condition or disease or are suitable to establish a Master Cell Bank from which sufficiently differentiated and / or functional and / or viable hepatocyte-like cells may subsequently be produced.

Described herein are methods for testing the differentiability of pluripotent stem cells (PSCs). The methods comprise assaying PSCs or PSC populations for differentiability marker mutation(s) and / or expression and determining the suitability of the PSCs or PSC populations for differentiation, e.g., into a product suitable for cell therapy. The methods can be used in cell banking and manufacturing cell therapies. Also provided herein are kits suitable for performing the PSC differentiability assessment methods disclosed herein.

The invention discloses a suspension culture cell monoclonal screening culture method. The method comprises the following steps: selecting cells under suspension culture conditions and inducing the cells to recover adherence; separating the single cells developed into obvious clones, and carrying out radioactive ray irradiation on the remaining cells, so that the remaining cells lose the multiplication capacity and become feeder layer cells; culturing the separated monoclonal cells, recording the culture time and culture environment, establishing a high-density cell bank, and establishing a growth time prediction formula for the multiple monoclonal cells according to the culture time; and calculating the specific time for culturing the required number of cells according to the growth time prediction formula established in the step S3. According to the method, the remaining cells are subjected to radioactive ray irradiation and are converted into feeder layer cells with important effects, so that the waste of cell resources is avoided, the flexible utilization of the cell resources is realized, and the treatment cost of the remaining cells is also remarkably reduced.